Validation of Analytic Methods for Biomarkers Used in Drug Development

被引:166
作者
Chau, Cindy H. [2 ]
Rixe, Olivier [2 ]
McLeod, Howard [1 ]
Figg, William D. [2 ]
机构
[1] Univ N Carolina, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC 27599 USA
[2] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-07-4535
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.
引用
收藏
页码:5967 / 5976
页数:10
相关论文
共 52 条
[1]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[2]   Key elements of bioanalytical method validation for small molecules [J].
Bansal, Surendra ;
DeStefano, Anthony .
AAPS JOURNAL, 2007, 9 (01) :E109-E114
[3]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[4]   Imatinib mesilate for the treatment of gastrointestinal stromal tumour [J].
Cassier, Philippe A. ;
Dufresne, Armelle ;
Arifi, Sarnia ;
El Sayadi, Hiba ;
Labidi, Inticlar ;
Ray-Coquard, Isabelle ;
Tabone, Severine ;
Meeus, Pierre ;
Ranchere, Dominique ;
Sunyach, Marie-Pierre ;
Decouvelaere, Anne-Valerie ;
Alberti, Laurent ;
Blay, Jean-Yves .
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) :1211-1222
[5]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[6]   Biomarkers in drug discovery and development: From target identification through drug marketing [J].
Colburn, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (04) :329-341
[7]   Biomarker method validation in anticancer drug development [J].
Cummings, J. ;
Ward, T. H. ;
Greystoke, A. ;
Ranson, M. ;
Dive, C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (04) :646-656
[8]   Practical management of patients with chronic myeloid leukemia receiving imatinib [J].
Deininger, MWN ;
O'Brien, SG ;
Ford, JM ;
Druker, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1637-1647
[9]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[10]   Imatinib alone and in combination for chronic myeloid leukemia [J].
Druker, BJ .
SEMINARS IN HEMATOLOGY, 2003, 40 (01) :50-58